PDCD1 and sensory peripheral neuropathy: When PD-1/PD-L1 inhibitors were compared with chemotherapy, the risk of peripheral sensory neuropathy of all grades was obviously lower [OR = 0.07, 95%CI:(0.04, 0.12), I2 = 13%, Z = 9.50(P < 0.00001); Figure 4A1] (24, 25, 30–34, 41, 46), while similar risk trends of grades 3–5 were seen between both arms [OR = 0.13, 95%CI:(0.04, 0.40), I2 = 0%, Z=3.57 (P = 0.0004); Figure 4A2] (24, 30–32, 34, 46).